Injectable Chemotherapy Downstaged Oral Squamous Cell Carcinoma from Nonresectable to Resectable in a Rescue Dog: Diagnosis, Treatment, and Outcome
Open Access
- 8 October 2018
- journal article
- case report
- Published by Wiley in Case Reports in Veterinary Medicine
- Vol. 2018, 1-6
Abstract
This case report documents the diagnosis, treatment, and outcome of a nonresectable oral squamous cell carcinoma in a dog with initial poor prognosis. An approximately 4-year-old female Staffordshire Bull Terrier presented with a large mass on the front of lower jaw which was diagnosed as oral papillary squamous cell carcinoma by histopathology. CT scans revealed invasion of the cancer to the frenulum of the tongue. The mass was inoperable due to location, expansiveness, and metastatic lymph nodes. The dog received 4 treatments of intralesional hyaluronan-platinum conjugates (HylaPlat™, HylaPharm LLC, Lawrence, Kansas) at 3-week intervals. Clinical chemistry and complete blood count were performed one week after each treatment and results were within normal limits. Complications included bleeding due to tumor tissue sloughing, as well as a single seizure due to unknown causes. Upon completion of chemotherapy, CT showed that the mass had regressed and was no longer invading the lingual frenulum, and multiple lymph nodes were free of metastasis. The mass thus became resectable and the dog successfully underwent rostral bilateral mandibulectomy. Over one year after chemotherapy and surgery, the cancer remains in complete remission.Keywords
Funding Information
- HylaPharm LLC (R01-CA173292)
- National Institutes of Health (R01-CA173292)
This publication has 15 references indexed in Scilit:
- Managing thrombocytopenia associated with cancer chemotherapy.2015
- Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugatesJournal of Drug Targeting, 2014
- In Vivo Efficacy of Nano Hyaluronan-Conjugated Cisplatin for Treatment of Murine Melanoma2014
- Efficacy and Toxicity of Peritumoral Delivery of Nanoconjugated Cisplatin in an In Vivo Murine Model of Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2013
- Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomasAmerican Journal of Veterinary Research, 2012
- Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivoThe American Journal of Surgery, 2011
- Carrier-based Intralymphatic Cisplatin Chemotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head & NeckTherapeutic Delivery, 2010
- Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in RodentsJournal of Pharmaceutical Sciences, 2010
- A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivoThe American Journal of Surgery, 2009
- Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell FactorCancer Research, 2007